CollabRx Appoints Paul Billings, MD, PhD to Board of Directors

Views tracker viewed for user 67568
CollabRx's picture
Printer-friendly versionPrinter-friendly version
By on April 8, 2014

Distinguished speaker, researcher, advocate, and thought leader on genomic medicine and precision oncology joins CollabRx board

San Francisco, Calif., April 8, 2014 – CollabRx, Inc. (NASDAQ: CLRX) today announced the appointment of Paul R. Billings, MD, PhD, FACP, FACMG to its Board of Directors.  Dr. Billings is a nationally recognized expert on genomic and precision medicine.

Dr. Billings is a board certified internist and clinical geneticist whose career has been devoted to  improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as Chief Medical Officer of Life Technologies, Inc. (acquired by Thermo Fisher Scientific, Inc. in March, 2014).  Currently, Dr. Billings serves in multiple roles in industry and government, including as Executive Chairman, Melanoma Diagnostics, Inc., and director of Trovagene, Inc., DecisionQ, Inc. and PAX Neuoscience, Inc. He was Co-Founder and first Medical Director of the Cordblood Registry, Inc., past Senior Physician and SVP of Laboratory Corporation of America, Inc. (LabCorp), Co-Founder and Past Director of Omicia, Inc., Founder and EVP of GeneSage, Inc., and past Director of, Inc.

Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. Dr. Billings was the former Director and Chief Science Officer of the Genomic Medicine Institute at El Camino Hospital.  He was also a member of the United States Dept. of Health and Human Services Secretary’s Advisory Committee on Genetics, Health and Society.

Dr. Billings has held academic appointments at prestigious universities including Harvard University, UCSF, Stanford University and U. C. Berkeley, and has served as a physician at numerous medical centers. He is the author of nearly 200 publications and books on experimental and clinical medicine. His work on genetic discrimination was instrumental in the creation and passage of the federal Genetic Information Non-Discrimination Act of 2008. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.

CollabRx can play a vital role in accelerating of the use of genomic information in routine clinical practice,” said Dr. Billings.  “The company’s innovative Therapy Finder apps and knowledge-based services for laboratories help physicians navigate the increasingly complex landscape of treatment options in oncology that are associated with tumor genetic profiles.  This “precision medicine” approach to cancer care enables physicians to consider all possible options in designing a treatment plan for their patients and could lead to optimal clinical outcomes.  I am pleased to contribute to the development of CollabRx as a member of its board of directors.”  “We are honored to have Dr. Billings join our board, and look forward to benefiting from his broad perspective, depth of experience and commitment to our vision,” said Thomas Mika, Chairman and CEO of CollabRx.

In addition to being appointed to the CollabRx board, Dr. Billings will serve as Chairman of its Nominating and Governance Committee, and as a member of the Compensation and Audit Committees.

About CollabRx

CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at

News Source : CollabRx Appoints Paul Billings, MD, PhD to Board of Directors

Copy this html code to your website/blog to embed this press release.